All In Biotech

Drug Trial Radar · NCT07241520

Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke

Phase III Clinical Trial to Evaluate the Efficacy and Safety of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke(SAIL)- a Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,096 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,096

Planned (sponsor's estimate)

Start

Dec 8, 2025

Primary completion

Jun 30, 2027

Study completion Nov 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
Beijing Tiantan Hospital
First posted
Nov 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.

Conditions

  • Acute Ischemic Stroke

Interventions

  • SHPL-49 InjectionDrug

    2 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7 days.

  • Placebo InjectionDrug

    2 ampoules of Placebo Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale (mRS), with scores of 0-1 at Day 90Time frame: 90±7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linfen Central Hospital

    Linfen, Shanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.